Pulmatrix, Inc. · NASDAQ:PULM
Pulmatrix — Investor Presentation (July 2022)
13 slides from Pulmatrix's investor presentation, Jul 12, 2022
Slide 1: Pulmatrix
PULMATRIixX NASDAQ: PULM
Slide 2: PUR3100: Inhaled DHE for Treatment of Acute Migraine
PUR3100 Inhaled Dihydroergotamine (DHE) for Treatment of Acute Migraine (QW) Significant unmet need in a large market represents fF ~$575M U.S. peak net revenue opportunity? Lung delivery offers many potential advantages including fast acting pain relief and symptom control with a favorable tolerabi
Slide 3: Acute Treatment of Migraine: Large underserved market
ute Treatment of Migraine: Large underserved market Large Market >1 billion worldwide >38 million U.S. Affects 3x’s more women than men Tk PULMATRiX Large Unmet Medical Need 75% of patients not actively treated with Rx’s due to poor efficacy 80% of patients on Rx’s would try new therapies High Pharm
Slide 4: DHE is effective for acute treatment of migraine
DHE is effective for acute treatment Suggested Migraine Model of migraine with aura regardless of time of administration relative to migraine onset? DHE has 5-HT,, receptor antagonist activity ~ involved in mood disorders? PULMATRiX DHE has D2 antagonist activity, anda dopamine ereeeetiar migraine a
Slide 5: Migraine — Pulmonary Inhaled DHE Therapy Potential Advantages
Migraine — Pulmonary Inhaled DHE Therapy Potential Advantages What Do Patients Wé on Fast onset of action Migraine upon : 24+ hour headache Inhaled preferred Absence of: through early Tinax awakening, quick to : relief through over intranasal, : Nausea, lethargy, and sustained peek intensity, rescue
Slide 6: MAP0004 Inhaled DHE
1 Actuation (N26) —+-2 Actuations (N=6) 2-4 Actuatons (N=12) -2-6 Actuatons (N=12) MAP0004 Inhaled DHE ™ Orally inhaled DHE suspension for pMDI =1 to 6 actuations (0.22 mg/actuation delivered dose)! =1 mg IV Bolus dose comparison’ «Very rapid T,,,, at all doses (superior to IN) 1 "Ciax lower than IV
Slide 7: DHE Efficacy is Driven by Peak Exposure
DHE Efficacy is Driven by Peak Exposure Peer analysis suggests ‘C,,,., is dose-dependent and the best P| % Pain Relief@2hrs (absolute) versus Cmax poooa—~=«RP# 0.5504 Maron “SC > Ps: ‘Bae GE C2 HPD Fon Ca baer cs Stserved in Pm PK Wal (2 mgm) : i & tf i Pain Relief @ 2hrs absolute response rate (%)
Slide 8: PUR3100 Pharmacokinetics Compare Favorably With MAP0004
PUR3100 Pharmacokinetics Compare Favorably With MAP0004 Dog inhaled kinetics predicts human inhaled kinetics AUC oye (ng*h/mL)/mg MAP0004 dog Dose Normalized PUR3100 7 pharmacokinetics achieves similar Meennaeg nz accurately pharmacokinetics MAP0004 Human? 9.22 predicts MAPO004 to MAPO004 7 human in
Slide 9: All PUR3100 Doses are Anticipated to Be in Therapeutic Window
All PUR3100 Doses are Anticipated to Be in Therapeutic Window Orally inhaled DHE (MAP0004) has a superior profile to other DHE Pend Prodictod Cmax at 0.5, 1.0 and 1.5mg nominal PUR3100 dose = 11 mg (MAP) >50% Emesis TS MAP O04 0.44 mg > MAPOD0$ 0.88 mg 10,000 Therapeutic Window = =*-STS1015.4 mg =>
Slide 10: PUR3100 Initial Phase Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics
PUR3100 Initial Phase 1 Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics To demonstrate safety and comparative bioavailability of PUR3100 (pulmonary inhaled) relative to |'V DHE Randomized Double-blind, Double-dummy Single Dose Study in 24 Healthy Volunteers haled Placebo + 1mg I
Slide 11: PUR3100 Ph2 Dose Confirmation Study Intended to Demonstrate Proof of Concept
PUR3100 Ph2 Dose Confirmation Study Intended to Demonstrate Proof of Concept and Enable Pivotal Study Study may be initiated in 2023 enabled by potential FDA meeting in Q1 2023 Phase 2-Dose Confirmation © Patients provided with dose to administer at home during next migraine within 28 days and recor
Slide 12: PUR3100: $575M Peak Net Revenue Potential at LOE in the U.S.
PUR3100: $575M Peak Net Revenue Potential at LOE in the U.S. Physician and Patient Feedback Payer Feedback % of triptan patients experiencing 40% ¥ a suboptimal response 5) nt generic treatmen % of patients ranking “starts to show failures required improvement by 30 minutes” as the or #1 most import
Slide 13: Pulmatrix
Pa PULMATRixX NASDAQ: PULM